Global Vulvar Cancer Market Research Report: Information by Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, and Basal Cell Carcinoma), Treatment Type (Chemotherapy, Surgery, Radiation Therapy, and Biologic Therapy), End User (Hospitals & Clinics, Research & Academic Institutes, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2025

ID: MRFR/MED/0914-HCR | February 2021 | Region: Global | 85 pages

Market Scenario, The global vulvar cancer market is expected to witness significant growth over the forecast period. The market was valued at approximately USD 681.85 million in 2018 and is projected to register a 6.2% CAGR over the forecast period., Vulvar cancers occur on the outer surface of the female genitalia and form a lump or a sore on the vulva that might cause itching in the region., Factors such as the rising prevalence of vulvar cancer are expected to drive market growth. According to an article published by the American Society of Clinical Oncology in March 2019, an estimated 6,070 women in the US were diagnosed with vulvar cancer. Moreover, increasing research and development expenditure in the field of oncology is also expected to boost market growth., However, the side effects of the treatment are expected to hamper the market growth. , , Segmentation, The global vulvar cancer market has been segmented into cancer type, treatment type, end user, and region. , Based on cancer type, the global vulvar cancer market has been segmented into vulvar squamous cell carcinoma, vulvar melanoma, adenocarcinoma, and basal cell carcinoma., The global vulvar cancer market, by treatment type, has been segmented into chemotherapy, surgery, radiation therapy, and biologic therapy. The surgery segment is further classified into laser surgery, excision, skinning vulvectomy, and radical vulvectomy., The global vulvar cancer market, by end user, has been segmented into hospitals & clinics, research & academic institutes, and others., The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The vulvar cancer market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. , The European vulvar cancer market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe. , The vulvar cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific., The Middle East & Africa vulvar cancer market is segmented into the Middle East and Africa., , Key Players , Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Novarti

Market Scenario
The global vulvar cancer market is expected to witness significant growth over the forecast period. The market was valued at approximately USD 681.85 million in 2018 and is projected to register a 6.2% CAGR over the forecast period.
Vulvar cancers occur on the outer surface of the female genitalia and form a lump or a sore on the vulva that might cause itching in the region.
Factors such as the rising prevalence of vulvar cancer are expected to drive market growth. According to an article published by the American Society of Clinical Oncology in March 2019, an estimated 6,070 women in the US were diagnosed with vulvar cancer. Moreover, increasing research and development expenditure in the field of oncology is also expected to boost market growth.
However, the side effects of the treatment are expected to hamper the market growth.

Segmentation
The global vulvar cancer market has been segmented into cancer type, treatment type, end user, and region.
Based on cancer type, the global vulvar cancer market has been segmented into vulvar squamous cell carcinoma, vulvar melanoma, adenocarcinoma, and basal cell carcinoma.
The global vulvar cancer market, by treatment type, has been segmented into chemotherapy, surgery, radiation therapy, and biologic therapy. The surgery segment is further classified into laser surgery, excision, skinning vulvectomy, and radical vulvectomy.
The global vulvar cancer market, by end user, has been segmented into hospitals & clinics, research & academic institutes, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The vulvar cancer market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European vulvar cancer market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe.
The vulvar cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The Middle East & Africa vulvar cancer market is segmented into the Middle East and Africa.

Key Players
Amgen Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Sanofi (France), and Johnson & Johnson Services, Inc. (US) are some of the key players operating in the global vulvar cancer market.

Regional Market Summary

Global Vulvar Cancer Market Share (%), by Region, 2018

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports
Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to dominate the global vulvar cancer market owing to the rising prevalence of vulvar cancer.
Europe is expected to hold the second-largest share of the vulvar cancer market owing to the presence of major market players such as F.Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, and Sanofi.
Asia-Pacific is expected to be the fastest-growing regional market owing to the increasing awareness regarding cancer and increasing R&D in the field of oncology.
The vulvar cancer market in the Middle East & Africa is expected to steadily grow during the forecast period owing to the high incidence rate of vulvar cancer.

Global Vulvar Cancer Market, by Cancer Type

Vulvar Squamous Cell Carcinoma

Vulvar Melanoma

Adenocarcinoma

Basal Cell Carcinoma

Global Vulvar Cancer Market, by Treatment Type

Chemotherapy

Surgery

Laser Surgery

Excision

Skinning Vulvectomy

Radical Vulvectomy

Radiation Therapy

Biologic Therapy

Global Vulvar Cancer Market, by End User

Hospitals and Clinics

Research and Academic Institutes

Others

Global Vulvar Cancer Market, by Region

Americas
- North America
- US
- Canada
- Latin America

Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe

Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific

Middle East & Africa
- Middle East
- Africa

Intended Audience

Biotechnology companies

Research institutes

Medical device companies

Pharmaceutical companies

Hospitals and clinics

Ambulatory surgical centers

Academic institutes

Government organizations

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL VULVAR CANCER MARKET, BY CANCER TYPE

6.1. Overview

6.2. Vulvar Squamous Cell Carcinoma

Market Estimates & Forecast, by Region, 2019–2025